

( (S (NP-SBJ National Patent Development Corp.)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 it)
                  (VP plans
                      (S (NP-SBJ *-1)
                         (VP to
                             (VP purchase
                                 (NP (NP (QP as many as 200,000) common shares)
				     (PP of
					 (NP its 81%-controlled Interferon Sciences Inc. unit)))
                                 (PP-LOC in
					 (NP periodic , open-market purchases)))))))))
     .))
( (S (NP-SBJ The 200,000 shares)
     (VP are
         (NP-PRD (NP (QP about 23) %)
                 (PP of
                     (NP (NP (NP Interferon 's)
                             common shares)
                         (ADJP outstanding))))
	 ,
	 (PP excluding
	     (NP (NP National Patent 's)
		 stake)))
     .))
( (S (S-ADV (NP-SBJ *-1)
	    (VP Noting
		(NP (NP the recent Food and Drug Administration approval)
		    (PP of
			(NP (NP Interferon 's)
			    genital warts treatment)))))
     ,
     (NP-SBJ-1 National Patent)
     (VP said
	 (SBAR 0
	       (S (NP-SBJ it)
		  (VP believes
		      (SBAR 0
			    (S (NP-SBJ (NP Interferon 's)
				       stock)
			       (VP is
				   (ADJP-PRD undervalued))))))))
     .))
